<DOC>
	<DOCNO>NCT00460356</DOCNO>
	<brief_summary>This clinical trial study glycoprotein glycan tissue blood sample patient stage IB-IVA cervical cancer undergo surgery remove pelvic abdominal lymph node . Studying sample tumor tissue blood patient cancer laboratory may help doctor learn change occur deoxyribonucleic acid ( DNA ) identify biomarkers related cancer . It may also help doctor learn far disease spread .</brief_summary>
	<brief_title>Glycoprotein Glycan Tissue Blood Samples Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery Remove Pelvic Abdominal Lymph Nodes</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Determine whether presence mutation T-synthase Cosmc and/or presence positive immunohistochemical expression Tn antigen sialyl Tn antigen tumor specimen associate progression-free overall survival patient stage IB2 , II , III , IVA cervical cancer undergo pelvic para-aortic ( abdominal ) lymphadenectomy . SECONDARY OBJECTIVES : I . Determine whether presence mutation T-synthase Cosmc and/or presence positive immunohistochemical expression Tn antigen sialyl Tn antigen tumor specimen associate lymph node metastasis local control . II . Identify glycoprotein profile customize gene expression array analysis tumor specimen glycan profile customized glycan array serum associate lymph node metastasis , local control , disease recurrence/progression , survival . III . Determine whether difference exist T-synthase Cosmc mutation , immunohistochemical expression Tn antigen sialyl Tn antigen , glycoprotein profiling ( use customize gene expression array analysis ) match primary tumor compare metastatic lymph node associate lymph node metastasis , local control , disease recurrence/progression , survival . IV . Identify difference glycoprotein expression profile glycan profile tumor specimen without mutation T-synthase Cosmc , tumor specimen without positive immunohistochemical expression Tn antigen sialyl Tn antigen associate lymph node metastasis , local control , disease recurrence/progression , survival . OUTLINE : Primary metastatic tumor specimen collect lymphadenectomy use tissue microarray analysis , mutational analysis T-synthase Cosmc , immunohistochemical stain Tn antigen sialyl Tn antigen , customize gene expression array analysis 400 gene associate glycobiology . Pre-lymphadenectomy blood collect patient baseline customize glycan array analysis 300 carbohydrate . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Patients primary , previously untreated , histologically confirm locoregionally advanced ( Stages IB2 , IIA &gt; 4 cm , IIBIVA ) invasive carcinoma cervix ( cell type ) undergo pelvic paraaortic ( abdominal ) lymphadenectomy determine presence absence lymph node metastasis Patients meet preentry requirement Patients block 25 unstained section formalinfixed paraffinembedded primary tumor available satisfy primary tumor requirement Patients sign approve informed consent authorization permit release personal health information Patients satisfy preentry requirement</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>